PDF herunterladen
Zeitschrift für Orthomolekulare Medizin 2020; 18(03): 29-36
DOI: 10.1055/a-1253-7373
Nährstoff spezial

Das Flavonoid Quercetin

Uwe Gröber
› Weitere Informationen
    Lizenzen und Reprints

Zusammenfassung

Quercetin gehört zur Gruppe der Flavonoide, die v. a. in Obst, Blatt- und Wurzelgemüse sowie einigen Getreidesorten enthalten sind. Sie weisen antioxidative, antiinflammatorische, antikanzerogene, endothelprotektive sowie immunmodulierende Eigenschaften auf.

Wissenschaftliche Untersuchungen in vitro und in vivo weisen auf präventive und therapeutische Wirkungen von Quercetin hin: u. a. zur Kardioprotektion, bei chronisch entzündlichen Darmerkrankungen, Allergien und Entzündungen, zur Tumorprotektion, bei Diabetes, venösen Erkrankungen sowie viralen Atemwegserkrankungen.

Schlüsselwörter

Quercetin - Flavonoid - Antioxidans


Publikationsverlauf

Artikel online veröffentlicht:
14. Oktober 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Frankel EN, Kanner J, German JB. et al. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 1993; 341 (8843): 454-457
    CrossrefPubMedGoogle Scholar
  • 2 Novoozi M, Angerson WJ, Lean ME. Effects of flavonoids and vitamin C on oxidative DNA damage to human lymphocytes. Am J Clin Nutr 1998; 67: 1210-1218
    CrossrefPubMedGoogle Scholar
  • 3 Petrakis PL. et al. Metabolic studies of quercetin labeled with C14 . Archive of Biochemistry and Biophysiology 1959; 85: 264-271
    CrossrefPubMedGoogle Scholar
  • 4 Hollmann PCH. et al. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr 1995; 62: 1276-1282
    CrossrefPubMedGoogle Scholar
  • 5 Frankel EN. et al. Inhibition of oxidation of human low-densty lipoprotein by phenolic substances in red wine. Lancet 1993; 341: 454-457
    CrossrefPubMedGoogle Scholar
  • 6 Luo M, Kannar K. et al. Inhibition of LDL oxidation by green tea extract. Lancet 1997; 349 (9048): 360-361
    CrossrefPubMedGoogle Scholar
  • 7 Chen L, Li J, Luo C. et al. Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): Structure-activity relationship studies reveal salient pharmacophore features. Bioorg Med Chem 2006; 14 (24) : 8295-8306
    CrossrefPubMedGoogle Scholar
  • 8 Seri J, Suwon K, Dong Hae S. et al. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem 2020; 35 (01) : 145-151
    CrossrefPubMedGoogle Scholar
  • 9 Yi L, Li Z, Yuan K. et al. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J Virol 2004; 78 (20) : 11334-11339
    CrossrefPubMedGoogle Scholar
  • 10 Zhang L, Lin D, Sun X. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 2020; 368: 409-412
    CrossrefPubMedGoogle Scholar
  • 11 Onal H. The possible effect of quercetin on prophylaxis and treatment of COVID-19. Clinical Trials.gov; 2020
    Google Scholar
  • 12 Hertog MGL, Feskens EJM. et al. Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen elderly study. Lancet 1993; 342: 1007-1011
    CrossrefPubMedGoogle Scholar
  • 13 Zhu QY, Huang Y, Chen ZY. Interaction between flavonoids and α-tocopherol in human low density lipoprotein – The Zutphen Elderly study. J Nutr Biochemistry 2000; 11 (01) : 14-21
    CrossrefPubMedGoogle Scholar
  • 14 Morales M, Lozoya X. Calcium-antagonist effect of quercetin on aortic smooth muscle. Planta Medica 1994; 60 (04) : 313-317
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 15 Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammmatory bowel disease. Gastroenterology 1984; 86: 453-460
    CrossrefPubMedGoogle Scholar
  • 16 Schneider H, Simmering R. et al. Degradation of quercetin-3-glucoside in gnotobiotic rats associated with human intestinal bacteria. J Appl Microbiol 2000; 89 (06) : 1027-1037
    CrossrefPubMedGoogle Scholar
  • 17 Jacobasch G, Schmiedl D. et al. Dietary resistant starch and chronic inflammatory bowel diseases. Int J Colorectal Dis 1999; 14 (4–5): 201-211
    CrossrefPubMedGoogle Scholar
  • 18 Wachtershauser A, Stein J. Rationale for the luminal provision of butyrate in intestinal diseases. Eur J Nutr 2000; 39 (04) : 164-171
    CrossrefPubMedGoogle Scholar
  • 19 Pearce FL, Befus AD, Bienenstock J. Mucosal mast cells. III. Effect of quercetin and other flavonoids on antigen-induced histamine secretion from rat intestinal mast cells. J Allergy Clin Immunol 1984; 73 (06) : 819-823
    CrossrefPubMedGoogle Scholar
  • 20 Busse WW. et al. Flavonoid modulation of human neutrophil function. J Allergy Clin Immunol 1984; 73: 801-809
    CrossrefPubMedGoogle Scholar
  • 21 Cruz T, Galvez J. et al. Oral administration of rutoside can ameliorate inflammatory bowel disease in rats. Life Science 1998; 62 (07) : 687-695
    CrossrefPubMedGoogle Scholar
  • 22 Segain JP. et al. Butyrate inhibits inflammatory responses through NF-κB inhibition: implications for Crohn’s disease. Gut 2000; 47 (03) : 397-403
    CrossrefPubMedGoogle Scholar
  • 23 Inan MS. et al. The luminal short-chain fatty acid butyrat modulates NF-κB activity in a human colonic epithelial cell line. Gastroenterol 2000; 118 (04) : 724-734
    CrossrefPubMedGoogle Scholar
  • 24 Scheppach W, Sommer H. et al. Effect of butyrat enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterol 1992; 103 (01) : 51-56
    CrossrefPubMedGoogle Scholar
  • 25 Ishikawa Y, Kitamura M. Bioflavonoid quercetin inhibits mitosis and apoptosis of glomerular cells in vitro and in vivo. Biochem Biophys Res Commun 2000; 279 (02) : 629-634
    CrossrefPubMedGoogle Scholar
  • 26 Le Marchand L, Murphy SP, Hankin JH. et al. Intake of flavonoids and lung cancer. J Natl Cancer Inst 2000; 92 (02) : 154-160
    CrossrefPubMedGoogle Scholar
  • 27 Nishino H. et al. Role of flavonoids in suppressing the enhacement of phopholipid metabolism by tumor promoters. Cancer Letters 1983; 21: 1-8
    CrossrefPubMedGoogle Scholar
  • 28 Duthie SJ, Dobson VL. Dietary flavonoids protect human colonocyte DNA from oxidative attack in vitro. Eur J Nutr 1999; 38 (01) : 28-34
    CrossrefPubMedGoogle Scholar
  • 29 Aherne SA, O‘Brien NM. Mechanism of protection by the flavonoids, quercetin and rutin, against tert-butylhydroperoxide- and menadione-induced DNA single strand breaks in Caco-2-cells. Free Radic Biol Med 2000; 29 (06) : 507-514
    CrossrefPubMedGoogle Scholar
  • 30 Novoozi M. et al. Effects of flavonoids and vitamin C on oxidative DNA damage to human lymphocytes. Am J Clin Nutr 1998; 67: 1210-1218
    CrossrefPubMedGoogle Scholar
  • 31 Middleton E. et al. Flavonoid inhibition of human basophil histamine release stimulated by various agents. Biochem Pharmacol 1984; 33: 3333-3338
    CrossrefPubMedGoogle Scholar
  • 32 Yoshimoto T. et al. Flavonoids: Potent inhibitors of arachidonic 5-lipoxygenase. Biochem Biophys Res Commun 1983; 116: 612-618
    CrossrefPubMedGoogle Scholar
  • 33 Ferrandiz ML, Alcaraz MJ. Antiinflammatoriy activity and inhibition of arachidonic acid metabolism by flavonoids. Agents Action 1991; 32: 283-287
    CrossrefPubMedGoogle Scholar
  • 34 Tarayre JP, Lauressergues H. Advantages of a combination of proteolytic enzymes, falvonoids and ascorbic acid in comparison with non-steroid anti-inflammatory agents. Arzneimittel Forschung 1977; 27: 1144-1149
    PubMedGoogle Scholar
  • 35 Gröber U. Orthomolekulare Medizin. Ein Leitfaden für Apotheker und Ärzte. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 1999
    Google Scholar
  • 36 Chaundry PS. et al. Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol 1983; 32: 1995-1998
    CrossrefPubMedGoogle Scholar
  • 37 Varma SD. et al. Diabetic cataracts and flavonoids. Science 1977; 195: 87-89
    CrossrefPubMedGoogle Scholar
  • 38 Kiesewetter H. et al. Buchweizenkraut-/Troxerutin-Kombination bei chronisch venöser Insuffizienz. Zeitschrift für Phytotherapie 1997; 18: 341-346
    Google Scholar
  • 39 Neumann HAM, van den Broek MJTB. A comparative clinical trial of graduated compression stockings and O-(β-hydroxyethyl)-rutosides (HR) in the treatment of patients with chronic venous insufficiency. Lymphology 1995; 19: 8-11
    Google Scholar
  • 40 Peres W, Tunon MJ. et al. The flavonoid quercetin ameliorates liver damage in rats with biliary obstruction. J Hepatol 2000; 33 (05) : 742-750
    CrossrefPubMedGoogle Scholar